نتایج جستجو برای: pancreatic targeting
تعداد نتایج: 231256 فیلتر نتایج به سال:
Most pancreatic cancer patients present with inoperable disease or develop metastases after surgery. Conventional therapies are usually ineffective in treating metastatic disease. It is evident that novel therapies remain to be developed. Transforming growth factor B (TGF-B) plays a key role in cancer metastasis, signaling through the TGF-B type I/II receptors (TBRI/II). We hypothesized that ta...
Pancreatic cancer is an aggressive malignancy with a dismal prognosis. To improve treatment options new treatments, such as adenoviral (Ad) gene therapy are necessary. However, low expression of the coxsackie and adenovirus receptor (CAR) in pancreatic cancer cells (PC) limits the therapeutic efficacy of these vectors. The aim of this study was to improve transduction of PC by recombinant adeno...
Pancreatic cancer is responsible for nearly 40,000 deaths in the U.S. annually, with a dismal 5-year survival rate below 7%. The poor therapeutic outcomes reflect a paucity of new approaches targeting the genomic underpinnings of pancreatic ductal adenocarcinomas (PDAC, the vast majority of pancreatic cancers) as well as our inability to overcome the desmoplastic stromal barrier characteristic ...
Pancreatic cancer is one of the deadliest types of cancer, and despite extensive basic and pre-clinical research efforts, existing therapeutics remain largely ineffective. During pancreatic cancer progression, neoplastic transformation of epithelial cells is typically accompanied by a fibrotic response, driven by activation of stromal cells, and which leads to extensive deposition and remodelin...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید